Overview

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborator:
National Cancer Institute (NCI)
Treatments:
Duloxetine Hydrochloride